Prostacyclin and thromboxane in chronic uremia: effect of hemodialysis.
To study the effects of uremia and hemodialysis on the production rates of antiaggregatory prostacyclin (PGI2) and proaggregatory thromboxane A2 (TxA2), we collected serial plasma samples from eight patients with chronic uremia before, during and after hemodialysis and assayed them for 6-keto-PGF1 alpha and TxB2, the stable metabolites of PGI2 and TxA2, respectively. In addition, the capacity of the platelets to produce TxB2 during spontaneous clotting was studied by measuring the TxB2 levels in serum incubated at +37 degrees C for 60 minutes. The PGI2 production of the uremia patients before hemodialysis was less (P less than 0.001) than that of healthy volunteers. It rose significantly following heparinization and remained elevated during hemodialysis. TxB2 generation by platelets during clotting was diminished in uremia. Plasma TxB2 levels were normal before, but increased during hemodialysis. Thus, profound changes in the PGI2/TxA2-system seem to be associated with uremia and hemodialysis.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D001792:Blood Platelets / Q000378:metabolism; D011464:Epoprostenol / Q000096:biosynthesis*; D005260:Female; D005921:Glomerulonephritis / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011453:Prostaglandins / Q000096:biosynthesis*; D011704:Pyelonephritis / Q000378:metabolism; D006435:Renal Dialysis; D013928:Thromboxane A2 / Q000096:biosynthesis*; D013929:Thromboxane B2 / Q000097:blood; D013931:Thromboxanes / Q000096:biosynthesis*; D014511:Uremia / Q000097:blood / Q000378:metabolism* / Q000628:therapy
D011453:Prostaglandins; D013931:Thromboxanes; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D006493:Heparin; D011464:Epoprostenol